DiaMedica Therapeutics Inc.: Business Overview, Financials & Competitive Analysis

DiaMedica Therapeutics Inc. Overview

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on preeclampsia, fetal growth restriction and acute ischemic stroke. DiaMedica's lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases.

Strategic Profile

The ReMEDy2 Phase 2/3 AIS Trial of DM199 surpassed 70% of required interim enrollment, with interim analysis planned in Q4 2026. Management anticipates four separate preeclampsia data readouts and a readout from the fetal growth restriction trial between now and the end of 2027, with these datasets anticipated to inform dose selection for a potential multi-national Phase 3 program in early-onset preeclampsia.

Competitive Landscape

DiaMedica's primary competition in the ischemic disease space includes larger established players developing stroke and maternal health therapeutics. Relevant competitors include players with acute ischemic stroke programs (major pharma and biotech firms with late-stage stroke candidates) and maternal health specialists focused on preeclampsia and fetal growth restriction. DiaMedica's differentiation centers on DM199's established use as a KLK1 therapeutic in Asia and first-mover status in Western clinical development for its target indications.

Industry Context

DiaMedica Therapeutics Inc. operates in Pharmaceuticals.

Key facts

Founded: 2000 · Headquarters: Minneapolis, US